Finally, the rate risk calculated from HR for DFS and OS showed a highly significant association, indicating that receiving brachytherapy may predict both cancer recurrence and cancer-specific death.
← all excerpts
Traditional Clinicopathological Biomarkers Still Determine Disease-Free and Overall Survival in Invasive Breast Cancer Patients: A Pilot Study.
1
—
—